Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRSD216 in elevated lipoprotein(a)
NCT07172646Phase 2Recruiting
- Sponsor
- Sirius Therapeutics
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of SRSD216 in hyperlipoproteinemia, sponsored by Sirius Therapeutics. Started Apr 2025; status: recruiting.
02
Drugs
SRSD216
03
Conditions
hyperlipoproteinemia
Beyond the preview
Go deeper on NCT07172646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172646.